Codexis Appoints Greg Hughes, Ph.D., as Vice President, Strategic Alliance & Product Development

  Codexis Appoints Greg Hughes, Ph.D., as Vice President, Strategic Alliance &
  Product Development

Business Wire

REDWOOD CITY, Calif. -- November 5, 2013

Codexis, Inc. (NASDAQ: CDXS), a developer of engineered enzymes for
pharmaceutical, biofuel and chemical production, today announced the
appointment of Greg Hughes, Ph.D., as Vice President, Strategic Alliance &
Product Development, effective October 28, 2013. Dr. Hughes spent the last 11
years in Process Chemistry at Merck with a primary focus in developing and
implementing biocatalysis technology.

“We are very pleased to have Greg join the Codexis team as we continue to
position our biocatalyst business for market leadership and growth,” said John
Nicols, President and CEO of Codexis. “Greg was a driving force behind our
landmark partnership with Merck for the development and deployment of a
biocatalytic production process for Merck’s type 2 diabetes drug Januvia®
(sitagliptin). He knows firsthand the value creation that Codexis’
biocatalysis technology can bring to our pharmaceutical customers. Greg can
help us break down potential internal resistance to adoption of new
technologies at large companies. In his role at Codexis, Greg will be working
to build deeper alliances with major pharmaceutical companies, while also
helping to develop new products to broaden the commercial applicability of our
biocatalyst platform.”

“Codexis has quickly become the market leader in biocatalysis for the
pharmaceutical industry, and I am very pleased to be joining the Company at
this time with so many near-term growth opportunities,” said Dr. Hughes. “Our
customized enzymes can benefit customers in both the pharmaceutical industry
and other complex chemistry markets, and I look forward to building off of my
previous experience working with Codexis to help grow both our customer and
product pipelines in the months ahead.”

Prior to joining Codexis, Dr. Hughes worked at Merck beginning in 2002 in a
variety of roles, most recently as Executive Director, Enabling Technologies
in the Process Chemistry department. His responsibilities at Merck were
focused on process chemistry and in particular on the application of
biocatalysis technology within Merck’s research and development and
manufacturing groups.

Dr. Hughes holds a Ph.D. in Organic Chemistry from the University of Toronto
and a B.S. in Chemistry from the University of New Brunswick. He completed his
postdoctoral work at the Massachusetts Institute of Technology.

About Codexis, Inc.

Codexis, Inc. engineers enzymes for pharmaceutical, biofuel and chemical
production. Codexis’ proven technology enables scale-up and implementation of
biocatalytic solutions to meet customer needs for rapid, cost-effective and
sustainable process development – from research to manufacturing. For more
information, see www.codexis.com.

Forward-Looking Statements

This press release contains forward-looking statements relating to the
expansion of Codexis’ pharmaceutical business, Codexis’ abilities to
capitalize on business opportunities in the pharmaceutical and other markets
and the benefits that Codexis’ enzymes can provide its customers. You should
not place undue reliance on these forward-looking statements because they
involve known and unknown risks, uncertainties and other factors that are, in
some cases, beyond Codexis’ control and that could materially affect actual
results. Factors that could materially affect actual results include Codexis’
dependence on a limited number of customers and a limited number of products
in its pharmaceutical business, Codexis’ abilities to develop and
commercialize new products for the pharmaceutical market, Codexis’ dependence
on its collaborators and the successful management of these relationships in
developing and commercializing new products, Codexis’ ability to deploy its
technology into market spaces adjacent to its pharmaceutical business and
Codexis’ customers receiving regulatory and market approval of their
pharmaceutical products. Additional factors that could materially affect
actual results can be found in Codexis’ Quarterly Report on Form 10-Q filed
with the Securities and Exchange Commission on August 9, 2013, including under
the caption “Risk Factors.” Codexis expressly disclaims any intent or
obligation to update these forward-looking statements, except as required by
law.

Contact:

Codexis, Inc.
Investors
Paul Cox, 212-362-1200
ir@codexis.com
or
Media
Jemma Connor, +44 161 359 3255
jemma.connor@notchcommunications.co.uk